Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive disorder. Disorders related with nerve and ganglia outside the brain and spinal cord are considered to be peripheral nervous system disorders. In this case, neurodegeneration occurs due to the abnormal buildup of iron in certain areas of the brain. It is caused due to the deficiency or absence of PKAN2 gene located on the chromosome 20p 13-p12.3. This disease involves progressive decline in mental and physical capabilities which affect a patient’s life. The disorder is characterized by progressive difficulty with movement. Movement abnormalities include rigidity, difficulty with walking, muscle spasms, difficulties with speech (dysarthria), and few of them also develop vision loss, paralysis, pain, etc. Additionally, a patient can experience psychiatric symptoms, which may include personality changes, depression, and dementia (loss of intellectual function). The prevalence of PKAN is estimated at 1 to 3 individuals per million globally. PKAN is one of the rare neurological disorders, hence it may often go unrecognized and misdiagnosed. Currently, there is no precise treatment available for individuals suffering from PKAN. The available treatments are focused toward particular symptoms shown by a patient. Presently, the research studies based on PKAN are focusing on better understating of the primary cause of the disorder which can help to find a more precise and reliable treatment.

The global pantothenate kinase-associated neurodegeneration market is anticipated to grow at a rapid pace in the next years. Increase in the global geriatric population, rise in investments in research & development, and focus on studies related to neurological diseases are the major drivers of the global market. The World Health Organization (WHO) has reported that approximately 14.1% of the global population is likely to suffer from various conditions related to neurologic disorder by 2025. This in turn will increase production of neurotherapeutic drugs. Additionally, technological advancements and rise in awareness about autosomal recessive neurodegenerative diseases such as pantothenate kinase-associated neurodegeneration (PKAN) are the other factors boosting market growth. However, rise in cost of treatment of diseases, side effects due to the treatment, strict guidelines followed by different countries are factors expected to hamper the growth of the market.

The global pantothenate kinase-associated neurodegeneration market can be segmented based on form, diagnostic test, treatment, and end-user. In terms of form, the global market can be bifurcated into classic and atypical. Classic PKAN generally appears in early childhood, causing serious problems with muscle movement that may worsen quickly. Atypical PKAN can appear later in the adolescence stage and progress slowly. Based on diagnostic test, the global pantothenate kinase-associated neurodegeneration market can be classified into genetic tests, MRI scan, and others. A genetic test detects the malfunctioning gene that may cause the disorder. However, these tests are not commonly available. Tests such as an MRI scan help to detect movement disorders. MRI scan generally shows iron deposits in the basal ganglia region of the brain. These are called as the "eye of the tiger" sign due to the way deposits appear in the MRI scan. This sign recommends a diagnosis of PKAN. In terms of treatment, the global market can be categorized into anti-convulsive drugs, drugs on dystonia, and other supportive treatment. Based on end-user, the global pantothenate kinase-associated neurodegeneration market can be segmented as hospitals, academic & research institutes, private clinics & others.

Geographically, the global pantothenate kinase-associated neurodegeneration market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market due to technological advancements, better reimbursement policies, and presence of key players. Additionally, increase in awareness among people about various neurological conditions and government initiatives are likely to drive the market. Europe is another major market for pantothenate kinase-associated neurodegeneration treatment.

Key players operating in the global pantothenate kinase-associated neurodegeneration market are Johnson & Johnson, Abbott Laboratories, Inc., Retrophin, Inc., Novartis AG, Sanofi, Pfizer, Inc., Becton, Dickinson and Company, Biogen, Inc., AstraZeneca plc, and GlaxoSmithKline, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Pantothenate Kinase Associated Neurodegeneration Market

Pre Book